Genovis (Q4 review): Growth and a big cash pile at rapidly contracting multiples - Redeye

Genovis' Q4 2025 report showed strong growth following the SEK10.9m ADC order as expected. Despite some fx-headwinds, the outlook for 2026 appears strong with improving demand among biotech customers and a net cash position of around 15% of market cap ready to be utilized. The stock trades at 22x-9x 2026e-2028e EV/EBITDA.

Länk till analysen i sin helhet: https://www.redeye.se/research/1148620/genovis-q4-review-growth-and-a-big-cash-pile-at-rapidly-contracting-multiples?utm_source=finwire&utm_medium=RSS